ProBioGen AG and EUCODIS Bioscience sign agreement to commercialize C-LiNK, A novel antibody drug conjugation technology

on .

Novel Enzymatic, 1-Step Site-Specific Protein Conjugation Technology for ADC Production

Berlin, Germany, and Vienna, Austria, April 19th: ProBioGen AG, a leading specialist for contract development and manufacturing of complex glycoproteins and EUCODIS Bioscience, an expert in enzyme engineering, today jointly announced the signature of an exclusive license agreement on C-LiNK (CTAT), an innovative, site-specific ADC conjugation technology. Under the agreement ProBioGen gains exclusive rights to commercialize EUCODIS’ enzymatic C-terminal linking technology, and to offer it, together with its antibody development services, royalty-free to ADC-developing parties.

Antibody Drug Conjugate Using CTAT Linker Technology Shows Superior Efficacy in Xenograft Trial

on .

CTATTM is an innovative enzymatic linker technology for conjugating different payloads with antibodies, without affecting their specificity, binding properties or stability. In the presented xenograft trial, the tested CTAT-ADC showed superior efficacy versus a commercially available ADC.

EUCODIS Bioscience participates in European ERA-IB project ChitoTex

on .

Scope of ChitoTex is to develop and produce new insect chitosan and chitosan based functional coatings for yarns and textile fabrics. The three-year project with seven academic and industry partners is funded through the ERA-NET Scheme of the 7th EU Framework Programme.